Neurogene Stock Technical Analysis
| NGNE Stock | 20.06 -2.24 -10.04% |
According to pricing data from the 13th of March 2026, Neurogene trades at 20.06 per share. Quantitative signals reflect Mean Deviation of 3.92, downside deviation of 4.19, and Risk Adjusted Performance of 0.0504. Volume-adjusted indicators are evaluated relative to historical ranges. Current technical signals are evaluated against industry dispersion.
Neurogene Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Neurogene, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to NeurogeneNeurogene | Build AI portfolio with Neurogene Stock |
Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 81.0 | Strong Buy | 7 | Odds |
Analyst recommendations for Neurogene are summarized across multiple research providers. The view also includes average analyst consensus. Analyst earnings estimates for Neurogene serve as the benchmark against which Neurogene's quarterly results are judged. Beats and misses relative to consensus EPS estimates often drive sharp short-term price reactions.
Understanding Neurogene includes distinguishing between market value and book value, where book value reflects Neurogene's accounting equity. Neurogene's market capitalization is 345.42 M. A P/B ratio of 1.3 indicates the market values Neurogene above its accounting book value. Enterprise value stands at 92.06 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
The concept of value for Neurogene differs from its quoted price, since each reflects a different lens. For Neurogene, key inputs include a P/B ratio of 1.3, ROE of -42.25%, and revenue of 925 K. Trading price represents the transaction level agreed by market participants.
What if' Analysis
Running a what-if backtest on Neurogene gives investors a practical way to test how changes in horizon, position size, or market timing might have affected the result. Used properly, this review helps investors decide whether Neurogene's historical reward profile was stable enough to support the current thesis.
| 12/13/2025 |
| 03/13/2026 |
Starting with 0.00 in Neurogene on December 13, 2025 and exiting today would produce 0.00 in total gains. That corresponds to a 0.0% net return in Neurogene overall over 90 days. Neurogene has comparable peers such as Lineage Cell, Ocugen, Fulcrum Therapeutics, Autolus Therapeutics, ADC Therapeutics, Benitec Biopharma, and Solid Biosciences. Peer context helps frame relative positioning. Neurogene is listed within United States regulated exchanges. More
Upside and Downside Indicators for Neurogene Overview
These indicators describe how Neurogene momentum evolves across recent price ranges. They compare current price to recent trend and sentiment readings.
| Downside Deviation | 4.19 | |||
| Information Ratio | 0.0601 | |||
| Maximum Drawdown | 31.07 | |||
| Value At Risk | -6.83 | |||
| Potential Upside | 8.73 |
Market Risk Indicators for Neurogene Overview
Risk measures here provide context on Neurogene's return distribution and drawdown behavior. The metrics rely on historical prices to describe variability over time.| Risk Adjusted Performance | 0.0504 | |||
| Jensen Alpha | 0.2863 | |||
| Total Risk Alpha | 0.568 | |||
| Sortino Ratio | 0.0736 | |||
| Treynor Ratio | 0.4787 |
Mean reversion opportunities in Neurogene's arise when market prices disconnect from fundamental anchors such as earnings, book value, or historical price-to-earnings multiples.
Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0504 | |||
| Market Risk Adjusted Performance | 0.4887 | |||
| Mean Deviation | 3.92 | |||
| Semi Deviation | 3.98 | |||
| Downside Deviation | 4.19 | |||
| Coefficient Of Variation | 1897.68 | |||
| Standard Deviation | 5.13 | |||
| Variance | 26.31 | |||
| Information Ratio | 0.0601 | |||
| Jensen Alpha | 0.2863 | |||
| Total Risk Alpha | 0.568 | |||
| Sortino Ratio | 0.0736 | |||
| Treynor Ratio | 0.4787 | |||
| Maximum Drawdown | 31.07 | |||
| Value At Risk | -6.83 | |||
| Potential Upside | 8.73 | |||
| Downside Variance | 17.52 | |||
| Semi Variance | 15.86 | |||
| Expected Short fall | -4.88 | |||
| Skewness | 0.8269 | |||
| Kurtosis | 2.0 |
Neurogene Backtested Returns
Neurogene remains characterized by a low volatility profile within the selected investment span. It records an Efficiency (Sharpe) Ratio of 0.0556, marking performance variability over 3 months. We identified twenty-six technical indicators influencing the company's volatility profile. Please review metrics such as risk-adjusted performance of 0.0504, downside deviation of 4.19, and mean deviation of 3.92 to assess internal risk calibration. On a scale of 0 to 100, Neurogene holds a performance score of 4. The firm shows a Beta (market volatility) of 0.54, which conveys possible diversification benefits within a given portfolio. With a sub-1 beta, Neurogene participates in market rallies at a reduced pace while also limiting downside exposure. Please double-check Neurogene's relationship between the skewness and day typical price, to make a quick decision on whether Neurogene's current price movements will revert.
Auto-correlation | -0.38 |
Poor reverse predictability
Neurogene shows poor reverse predictability when comparing price series from 13th of December 2025 to 27th of January 2026 against from 27th of January 2026 to 13th of March 2026. A strong serial relationship would imply that Neurogene's recent trajectory contains information about its near-term direction. With a serial correlation of -0.38, just about 38.0% of Neurogene's price variation is attributable to patterns in preceding intervals. Given that Neurogene has negative autocorrelation for the selected time horizon, market participants may evaluate potential contrarian price behavior over comparable future intervals.
| Correlation Coefficient | -0.38 | |
| Spearman Rank Test | -0.43 | |
| Residual Average | 0.0 | |
| Price Variance | 4.9 |
This technical analysis view for Neurogene focuses on price, volume, and trend behavior. Typical tools include moving averages, relative strength index, regressions, and price correlations.
Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Neurogene volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Technical Analysis Methodology & Indicators
Technical analysis of Neurogene evaluates price structure, momentum, and volatility clustering. Oscillator extremes can precede mean reversion under certain regimes. Neurogene has a market cap of 345.42 M, ROE of -42.25%.
For Neurogene, this section uses periodic company reporting and market reference feeds with Macroaxis normalization rules applied to keep cross-asset comparisons consistent. Analyst inputs may be included when coverage is available. Intraday timing differences may exist.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial BoardNeurogene Technical Indicators
A technical review of Neurogene can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. The stronger process confirms one signal with others instead of reacting to one pattern in isolation.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0504 | |||
| Market Risk Adjusted Performance | 0.4887 | |||
| Mean Deviation | 3.92 | |||
| Semi Deviation | 3.98 | |||
| Downside Deviation | 4.19 | |||
| Coefficient Of Variation | 1897.68 | |||
| Standard Deviation | 5.13 | |||
| Variance | 26.31 | |||
| Information Ratio | 0.0601 | |||
| Jensen Alpha | 0.2863 | |||
| Total Risk Alpha | 0.568 | |||
| Sortino Ratio | 0.0736 | |||
| Treynor Ratio | 0.4787 | |||
| Maximum Drawdown | 31.07 | |||
| Value At Risk | -6.83 | |||
| Potential Upside | 8.73 | |||
| Downside Variance | 17.52 | |||
| Semi Variance | 15.86 | |||
| Expected Short fall | -4.88 | |||
| Skewness | 0.8269 | |||
| Kurtosis | 2.0 |
March 13, 2026 Daily Trend Indicators
A technical review of Neurogene can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. The stronger process confirms one signal with others instead of reacting to one pattern in isolation.
| Accumulation Distribution | 0.00 | ||
| Daily Balance Of Power | -Huge | ||
| Rate Of Daily Change | 0.90 | ||
| Day Median Price | 20.06 | ||
| Day Typical Price | 20.06 | ||
| Price Action Indicator | -1.12 |
Popular Tools for Neurogene Stock analysis
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Global Correlations Find global opportunities by holding instruments from different markets |